Skip to content

Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold LGND on Sep 3, 2026

Data as of Oct 16

▼ SELL$116K400 shares at $288.98Andrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc
Watch LGND
Traded
Sep 3, 2026
Disclosed
Sep 8, 2026
Filed
5 days after the trade · late

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals, sold LGND on Sep 3, 2026TRADEDDISCLOSED
LGNDSimilar stocks (XLV — its sector index fund), rebased to LGND's price on the disclosure day
LGND since disclosure
+2.3%
after the sale
Similar stocks (XLV) since disclosure
+5.7%
XLV — its sector index fund

Change in closing price from Sep 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$606Kdisclosed Sep 8 · filed 5 days after the trade · late
  2. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$111Kdisclosed Sep 8 · filed 5 days after the trade · late
  3. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$513Kdisclosed Sep 8 · filed 5 days after the trade · late
  4. ▼ SELLAndrew Reardon CLO & SecretaryLGND Ligand Pharmaceuticals Inc$85.2Kdisclosed Sep 8 · filed 5 days after the trade · late

See every trade on LGND →